Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Lemieux RM"'
Autor:
Freibaum BD; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Messing J; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Nakamura H; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Yurtsever U; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Wu J; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Kim HJ; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Hixon J; Faze Medicines , Cambridge, MA, USA., Lemieux RM; Faze Medicines , Cambridge, MA, USA., Duffner J; Faze Medicines , Cambridge, MA, USA., Huynh W; Faze Medicines , Cambridge, MA, USA., Wong K; Faze Medicines , Cambridge, MA, USA., White M; Faze Medicines , Cambridge, MA, USA., Lee C; Faze Medicines , Cambridge, MA, USA., Meyers RE; Faze Medicines , Cambridge, MA, USA., Parker R; Department of Biochemistry, University of Colorado, Boulder, CO, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Taylor JP; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Publikováno v:
The Journal of cell biology [J Cell Biol] 2024 Mar 04; Vol. 223 (3). Date of Electronic Publication: 2024 Jan 29.
Autor:
Chen Y; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Nagaraja NV; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.) raj.nagaraja@servier.com., Fan B; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Utley L; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Lemieux RM; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Popovici-Muller J; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Dang L; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Kim H; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Yan L; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Su SM; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Biller SA; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Yang H; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2021 Oct; Vol. 49 (10), pp. 870-881. Date of Electronic Publication: 2021 Jul 28.
Autor:
Kliche, Johanna1 (AUTHOR), Simonetti, Leandro1 (AUTHOR), Krystkowiak, Izabella2 (AUTHOR), Kuss, Hanna1,3 (AUTHOR), Diallo, Marcel4 (AUTHOR), Rask, Emma1 (AUTHOR), Nilsson, Jakob4 (AUTHOR), Davey, Norman E2 (AUTHOR) norman.davey@icr.ac.uk, Ivarsson, Ylva1 (AUTHOR) ylva.ivarsson@kemi.uu.se
Publikováno v:
Molecular Systems Biology. Sep2024, Vol. 20 Issue 9, p1025-1048. 24p.
Autor:
Giblin Pa, Lemieux Rm
Publikováno v:
Current pharmaceutical design. 12(22)
Over the past decade, Lymphocyte Function-Associated Antigen-1 (LFA-1, alphaLbeta2, CD11a/CD18) has emerged as an attractive therapeutic target for the treatment of multiple inflammatory diseases. Its established role in the trafficking and activatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f049679bdf3cfa89c13c9922fa5c5dcc
https://pubmed.ncbi.nlm.nih.gov/16918410
https://pubmed.ncbi.nlm.nih.gov/16918410
Autor:
Popovici-Muller J; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Lemieux RM; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Artin E; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Saunders JO; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Salituro FG; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Travins J; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Cianchetta G; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Cai Z; PharmaResources, Shanghai 201201, China., Zhou D; PharmaResources, Shanghai 201201, China., Cui D; PharmaResources, Shanghai 201201, China., Chen P; PharmaResources, Shanghai 201201, China., Straley K; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Tobin E; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Wang F; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., David MD; INSERM U1170 and Gustave Roussy, Villejuif 94800, France., Penard-Lacronique V; INSERM U1170 and Gustave Roussy, Villejuif 94800, France., Quivoron C; INSERM U1170 and Gustave Roussy, Villejuif 94800, France., Saada V; INSERM U1170 and Gustave Roussy, Villejuif 94800, France., de Botton S; INSERM U1170 and Gustave Roussy, Villejuif 94800, France., Gross S; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Dang L; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Yang H; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Utley L; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Chen Y; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Kim H; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Jin S; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Gu Z; ChemPartner, Shanghai 201203, China., Yao G; ChemPartner, Shanghai 201203, China., Luo Z; ChemPartner, Shanghai 201203, China., Lv X; ChemPartner, Shanghai 201203, China., Fang C; ChemPartner, Shanghai 201203, China., Yan L; ChemPartner, Shanghai 201203, China., Olaharski A; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Silverman L; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Biller S; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Su SM; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States., Yen K; Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2018 Jan 19; Vol. 9 (4), pp. 300-305. Date of Electronic Publication: 2018 Jan 19 (Print Publication: 2018).
Autor:
Horan JC; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States. Electronic address: joshua.horan@proteostasis.com., Kuzmich D; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Liu P; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., DiSalvo D; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Lord J; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Mao C; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Hopkins TD; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Yu H; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Harcken C; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Betageri R; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Hill-Drzewi M; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Patenaude L; Inflammation and Immunology, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Patel M; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Fletcher K; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Terenzzio D; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Linehan B; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Xia H; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Patel M; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Studwell D; Non-Clinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Miller C; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Hickey E; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Levin JI; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Smith D; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Kemper RA; Non-Clinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Modis LK; Inflammation and Immunology, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States., Bannen LC; Medicinal Chemistry, Exelixis, 210 East Grand Avenue, South San Francisco, CA 94080, United States., Chan DS; Medicinal Chemistry, Exelixis, 210 East Grand Avenue, South San Francisco, CA 94080, United States., Mac MB; Medicinal Chemistry, Exelixis, 210 East Grand Avenue, South San Francisco, CA 94080, United States., Ng S; Medicinal Chemistry, Exelixis, 210 East Grand Avenue, South San Francisco, CA 94080, United States., Wang Y; Medicinal Chemistry, Exelixis, 210 East Grand Avenue, South San Francisco, CA 94080, United States., Xu W; Medicinal Chemistry, Exelixis, 210 East Grand Avenue, South San Francisco, CA 94080, United States., Lemieux RM; Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877, United States.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2016 Jan 15; Vol. 26 (2), pp. 466-471. Date of Electronic Publication: 2015 Nov 26.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Khalil, Ahmed F.1 (AUTHOR) ahmed.faisal@pharm.tanta.edu.eg, El-Moselhy, Tarek F.1 (AUTHOR), El-Bastawissy, Eman A.1 (AUTHOR), Abdelhady, Rasha2 (AUTHOR), Younis, Nancy S.3 (AUTHOR), El-Hamamsy, Mervat H.1 (AUTHOR)
Publikováno v:
Journal of Enzyme Inhibition & Medicinal Chemistry. Dec2023, Vol. 38 Issue 1, p1-22. 22p.
Autor:
Lian, Yu1,2 (AUTHOR), Ti, Juanjuan1,2 (AUTHOR), Ma, Liangming1,2 (AUTHOR), Wei, Jia1,2 (AUTHOR) jiawei@tjh.tjmu.edu.cn, Gao, Zhilin1,2 (AUTHOR) jiawei@tjh.tjmu.edu.cn
Publikováno v:
Hematology. Dec2023, Vol. 28 Issue 1, p1-11. 11p.
Publikováno v:
JAMA Oncology; Oct2024, Vol. 10 Issue 10, p1417-1425, 9p